1.
Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011)
Rodriguez-Avial C, Rodriguez-Avial I, Hernandez E, Picazo JJ.
Rev Esp Quim 2013; 26:43–46.

2.
Intravenous Fosfomycin for the treatment of hospitalized patients with serious infections
Shorr AF, Pogue JM, Mohr JF.
Expert Review of Antiinfective Therapy 2017; DOI:10.1080/14787210.2017.1379897
PMID: 28901793